Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Thu, 10 Sep 2026 09:00:00 -0400

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana

State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season

SALT LAKE CITY, Sept. 10, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the completion of two new Vector Smart® mosquito surveillance laboratory installations in

Co-Diagnostics Completes New Vector Smart® Laboratory Installations Amid Rising Dengue Activity in Florida

Thu, 10 Sep 2026 09:00:00 -0400

Two full laboratory installations completed in Florida; installation and customer training underway in Indiana

State surveillance has recorded 73 locally acquired dengue cases and identifies 14 dengue-positive mosquito pools in Florida this season

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Mon, 24 Aug 2026 16:38:35 -0400

Co-Diagnostics (NASDAQ: CODX) filed for up to 3,404,724 share offering by selling stockholders.

Co-Diagnostics (CODX) files for 3.4M share offering by selling stockholders

Mon, 24 Aug 2026 16:38:35 -0400

Co-Diagnostics (NASDAQ: CODX) filed for up to 3,404,724 share offering by selling stockholders.

Form S-3 Co-Diagnostics, Inc.

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968521.html

Form S-3 Co-Diagnostics, Inc.

Mon, 24 Aug 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260824/26968521.html

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

SALT LAKE CITY, Aug. 18, 2026 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) ("Co-Dx" or "the Company"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced that Company Chief Commercialization Officer Seth Egan recently participated in the Salt Lake Business Journal's 2026 Medical Devices and Innovation Roundtable event, held on Thursday, August 13 and moderated

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

Co-Diagnostics Participates in Medical Devices and Innovations Roundtable Media Event

Tue, 18 Aug 2026 09:30:00 -0400

Company Chief Commercialization Officer represented Co-Dx in an event featuring other industry stakeholders held on August 13 in Salt Lake City, UT

Maxim Group Upgrades Co-Diagnostics (CODX) to Buy

Mon, 17 Aug 2026 08:19:37 -0400

Maxim Group analyst Jason McCarthy upgraded Co-Diagnostics (NASDAQ: CODX) from Hold to Buy with a price target of $4.00.

For an analyst ratings summary and ratings history on Co-Diagnostics click here. For more ratings news on Co-Diagnostics click here.

Shares of Co-Diagnostics closed at $1.40 yesterday.

Form SCHEDULE 13G Co-Diagnostics, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26926143.html

Form SCHEDULE 13G Co-Diagnostics, Inc. Filed by: ARMISTICE CAPITAL, LLC

Fri, 14 Aug 2026 10:08:00 -0400

si-local-file:///var/storage/secattach/20260814/26926143.html

Form 10-Q Co-Diagnostics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921109.html

Form 10-Q Co-Diagnostics, Inc. For: Jun 30

Thu, 13 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260813/26921109.html

Form 8-K Co-Diagnostics, Inc. For: Aug 13

Thu, 13 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26920622.html

Form 8-K Co-Diagnostics, Inc. For: Aug 13

Thu, 13 Aug 2026 16:03:00 -0400

si-local-file:///var/storage/secattach/20260813/26920622.html

Co-Diagnostics (CODX) Tops Q2 EPS by $1.54, Beats on Revenue

Thu, 13 Aug 2026 16:02:37 -0400

Co-Diagnostics (NASDAQ: CODX) reported Q2 EPS of ($1.46), $1.54 better than the analyst estimate of ($3.00). Revenue for the quarter came in at $170 thousand versus the consensus estimate of $132.58 thousand.

For earnings history and earnings-related data on Co-Diagnostics (CODX) click here.

Co-Diagnostics Reports Second Quarter 2026 Financial Results

Thu, 13 Aug 2026 16:01:00 -0400